Mutual Advisors LLC Grows Position in AstraZeneca PLC $AZN

Mutual Advisors LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 25.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,167 shares of the company’s stock after purchasing an additional 2,712 shares during the period. Mutual Advisors LLC’s holdings in AstraZeneca were worth $957,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SCS Capital Management LLC purchased a new position in AstraZeneca during the first quarter valued at $3,066,000. Robbins Farley purchased a new position in AstraZeneca during the second quarter valued at $1,857,000. Oliver Luxxe Assets LLC lifted its position in shares of AstraZeneca by 6.0% in the second quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after acquiring an additional 4,449 shares in the last quarter. Alhambra Investment Management LLC purchased a new position in shares of AstraZeneca in the second quarter valued at about $320,000. Finally, Community Trust & Investment Co. lifted its position in shares of AstraZeneca by 21.2% in the second quarter. Community Trust & Investment Co. now owns 226,161 shares of the company’s stock valued at $15,804,000 after acquiring an additional 39,488 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

NASDAQ:AZN opened at $84.69 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $262.66 billion, a P/E ratio of 31.84, a P/E/G ratio of 1.56 and a beta of 0.36. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The business’s 50-day moving average is $80.23 and its 200 day moving average is $73.86.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. The company had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.24 earnings per share. On average, equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s payout ratio is presently 37.97%.

Analysts Set New Price Targets

Several equities analysts have recently commented on AZN shares. Berenberg Bank set a $97.00 price objective on AstraZeneca in a research report on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.